Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Open-market sale Chief Commercial Officer sold 515 shares at $3.63 ($1,871)
  2. 4 Grant or award Atillasoy Ercem acquired 14,000 shares (grant or award)
  3. 4 Grant or award Chief Executive Officer acquired 48,125 shares (grant or award)
  4. 4 Open-market sale Director sold 65,725 shares at $3.67 ($241,106)
  5. 4 Open-market sale Chief Executive Officer sold 29,135 shares at $4.33 ($126,257)
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Open-market sale Chief Commercial Officer sold 15,262 shares at $4.40 ($67,167)
  14. 4 Open-market buy Director bought 5,000 shares at $4.64 ($23,197)
  15. 4 Open-market sale Director sold 4,227 shares at $5.87 ($24,812)
  16. 4 Open-market sale Director sold 1,162 shares at $6.68 ($7,767)
  17. 4 Open-market sale Chief Commercial Officer sold 852 shares at $6.68 ($5,695)
  18. 4 Open-market sale Atillasoy Ercem sold 2,040 shares at an average $6.04 ($12,329)
  19. 4 Open-market sale Chief Accounting Officer sold 276 shares at $6.68 ($1,845)
  20. 4 Grant or award Chief Accounting Officer acquired 17,442 shares (grant or award)

Page 12 of 19 · 363 filings